### [Dréan et al. Page 2022][1] PARP inhibitor (PARPi) resistance is often associated with “revertant” mutations that restore BRCA1 or BRCA2 gene function. Drean and colleagues used CRISPR-Cas9 mutagenesis to model these reversion mutations, finding that PARPi treatment selects for revertant

中文翻译：

---

本期要点

### [Dréan等。Page 2022] [1] PARP抑制剂（PARPi）耐药性通常与恢复BRCA1或BRCA2基因功能的“回复”突变相关。Drean及其同事使用CRISPR-Cas9诱变对这些回复突变进行建模，发现PARPi治疗选择了回复剂